ZYPREXA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zyprexa, and what generic alternatives are available?
Zyprexa is a drug marketed by Cheplapharm and is included in four NDAs.
The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Summary for ZYPREXA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 147 |
Clinical Trials: | 130 |
Patent Applications: | 3,706 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZYPREXA |
What excipients (inactive ingredients) are in ZYPREXA? | ZYPREXA excipients list |
DailyMed Link: | ZYPREXA at DailyMed |
Recent Clinical Trials for ZYPREXA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oregon Health and Science University | Phase 2 |
OHSU Knight Cancer Institute | Phase 2 |
Yale University | Phase 2 |
Pharmacology for ZYPREXA
Drug Class | Atypical Antipsychotic |
Anatomical Therapeutic Chemical (ATC) Classes for ZYPREXA
US Patents and Regulatory Information for ZYPREXA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cheplapharm | ZYPREXA | olanzapine | INJECTABLE;INTRAMUSCULAR | 021253-001 | Mar 29, 2004 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-006 | Sep 9, 1997 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-003 | Sep 30, 1996 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cheplapharm | ZYPREXA ZYDIS | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021086-002 | Apr 6, 2000 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-001 | Dec 11, 2009 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZYPREXA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-002 | Sep 30, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-001 | Sep 30, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-003 | Sep 30, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-004 | Sep 30, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-005 | Sep 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ZYPREXA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Eli Lilly Nederland B.V. | Zyprexa Velotab | olanzapine | EMEA/H/C/000287 AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. |
Authorised | no | no | no | 2000-02-03 | |
Eli Lilly Nederland B.V. | Zypadhera | olanzapine | EMEA/H/C/000890 Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine. |
Authorised | no | no | no | 2008-11-19 | |
Eli Lilly Nederland B.V. | Zyprexa | olanzapine | EMEA/H/C/000115 Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate. |
Authorised | no | no | no | 1996-09-27 | |
Krka | Zalasta | olanzapine | EMEA/H/C/000792 Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. |
Authorised | yes | no | no | 2007-09-27 | |
Mylan Pharmaceuticals Limited | Olanzapine Mylan | olanzapine | EMEA/H/C/000961 AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. |
Authorised | yes | no | no | 2008-10-06 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ZYPREXA
See the table below for patents covering ZYPREXA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 112575 | 4-Substituted 2-methyl-10h-thieno [2,3-b][1,5]benzodiazepine | ⤷ Try a Trial |
Panama | 8353701 | PROCEDIMIENTO Y FORMA CRISTALINAS DE 2-METIL-TIENO-BENZODIACEPINA. | ⤷ Try a Trial |
Denmark | 0733367 | ⤷ Try a Trial | |
Slovenia | 9620040 | Postopek in kristalne oblike 2-metil-tieno-benzodiazepina (PROCESS AND CRYSTAL FORMS OF 2-METHYL-THIENO-BENZODIAZEPINE) | ⤷ Try a Trial |
Brazil | 9711541 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZYPREXA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0454436 | SPC/GB96/058 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 |
0454436 | C970015 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927 |
0454436 | 9/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927 |
0454436 | 97C0012 | Belgium | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927 |
0454436 | CA 2001 00042 | Denmark | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |